Evidence map›Paper›PMID 41315667›Full record

ArticleOncogene2026

SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.

Shuang Liu, Yunlong He, Xin Ning, Wei Xu, Xiaowei Hu, Ling Qin, Yupeng Yang, Xihai Chen, Rong Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuang Liu *Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Yunlong He *Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Xin Ning *Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Wei XuDepartment of Gynecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Xiaowei HuDepartment of Head and Neck and Genito-Urinary Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Ling QinDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Yupeng YangDepartment of General Surgery, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Xihai ChenDepartment of General Surgery, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. maronghai@163.com.
Rong MaDepartment of Gynecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. 600543@hrbmu.edu.cn.ORCID http://orcid.org/0009-0009-2060-9853

Funding

Natural Science Foundation of Heilongjiang Province No. LH2020H124
6 · The paper itself

Abstract

In the treatment of ovarian cancer, PARP inhibitors such as olaparib have shown promise, yet resistance in advanced cases remains a significant challenge. Our study identified SLC7A5 as a key gene associated with olaparib resistance through differential gene expression and prognostic analysis. High SLC7A5 expression was found to correlate with poor prognosis. In vivo and in vitro experiments revealed that SLC7A5 enhances olaparib resistance by stabilizing ACLY and promoting de novo lipid synthesis via the ERBB2 axis, independent of leucine. Mechanistically, SLC7A5 upregulates ERBB2 transcription through ELK1, and ERBB2 competes with CUL3 to prevent ACLY degradation. These findings suggest that targeting SLC7A5 may reverse olaparib resistance, offering new strategies for combination therapies and improving clinical outcomes in ovarian cancer treatment.

Indexed as

Amino Acid Transport System y+Drug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesLipidsOvarian NeoplasmsPhthalazinesPiperazinesAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMicePoly(ADP-ribose) Polymerase InhibitorsXenograft Model Antitumor AssaysAmino Acid Transport System y+ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLipidsolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID41315667
PMCPMC12738383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.